All Articles

As AI reshapes business, an exclusive executive retreat argues that our greatest performance tool isn't technology, but ethical, resilient human leadership.

As advanced therapies reshape medicine, the race to control their complex supply chains heats up. Resonant's latest acquisition places it at the heart of Europe's booming market.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

A $1M payout for a Kentucky motorcycle crash reveals the hidden economics of catastrophic injury, complex legal strategy, and the price of safety on our roads.

NevGold's executive shuffle isn't just a personnel change. It's a calculated pivot from exploration to development, signaling a new era for its key assets.

A new partnership signals a tectonic shift in wealth management, moving from standalone products to integrated platforms built for mass personalization.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

The medtech firm swung from a massive loss to a tiny profit by slashing costs and expanding in the U.S. But is this a sustainable turnaround or a risky gamble?

WIGA's new campaign addresses problem gambling with a positive message, targeting the risks of emerging digital betting platforms aimed at Washington's youth.

As AI agents multiply, Cyera's $1B acquisition of Oasis Security aims to police them. But can a single platform truly govern a silent, autonomous workforce?

Inovalon's ScriptMed now electronically transfers specialty scripts, ending the fax-and-call era to speed up patient care and slash pharmacy workloads.

Behind a simple partnership lies a major shift. Yuno and Revolut are building the rails for a new era of seamless, AI-driven global commerce for millions.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Most bad business data comes from good intentions but biased questions. A new browser extension from CogBias AI aims to fix this problem in real time.

August saw a mere 36.5K jobs added, but the real story is AI's subtle takeover, creating a 19% employment gap for young workers in exposed roles.

A new partnership to standardize vehicle displays is more than a tech upgrade; it’s a strategic maneuver to dismantle the costly walled gardens of the auto industry.

Global medical device registries are riddled with errors, leading to costly mistakes. A new analysis reveals why row counts lie and what it means for your business.

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

TOYO Co., Ltd. is betting its future on controlling the entire solar supply chain. As its CSO meets investors, can this bold strategy navigate trade risks?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.